HCPCS Level II code J3489 designates a 1 mg injection of zoledronic acid, a parenteral bisphosphonate used in clinical practice for conditions requiring anti-resorptive therapy. Nationally, this code matters for accurate drug billing, inventory tracking, and outpatient infusion reimbursement because zoledronic acid is commonly administered in infusion suites and clinic settings.

Key payers included in this overview are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of what J3489 represents clinically and administratively, plus an overview of typical sites of service. The publication outlines benchmark considerations for coverage and payment, common modifier usage for billing scenarios, and clinical context for use of zoledronic acid in outpatient infusion settings. Where payer-specific policies exist, the analysis summarizes standard coverage themes and prior authorization patterns.

This summary equips clinicians, billing staff, and policy analysts with the core coding and service-context information needed to identify when J3489 applies, how it is presented on service lines, and what elements to review in payer policies and claim adjudication workflows.